Sutro Biopharma (NASDAQ: STRO) will announce its fourth-quarter earnings for 2025 on Thursday, March 12, 2025, before the market opens. Analysts anticipate a loss of $4.66 per share, alongside projected revenue of $9.263 million for the quarter. Details for an upcoming conference call, scheduled for Friday, March 27, 2026, at 4:00 PM ET, are available on the company’s earnings report page.
Sutro Biopharma’s shares opened at $24.98 on the previous trading day. The company holds a market capitalization of $212.58 million, with a price-to-earnings (P/E) ratio of -0.96 and a beta of 1.47. Over the past year, the stock has experienced significant volatility, with a low of $5.23 and a high of $26.54. The fifty-day moving average stands at $15.86, while the 200-day moving average is $11.62.
Analysts Provide Insights on Sutro Biopharma
Recent analysis from various financial institutions indicates a mixed outlook for Sutro Biopharma. On December 2, analysts at Wedbush reaffirmed a “neutral” rating while significantly raising their price target to $100.00, up from $20.00. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on December 17, showcasing confidence in the company’s potential.
Further, HC Wainwright updated its rating to “neutral” and adjusted its price target to $10.00 on December 22. Citigroup upgraded Sutro Biopharma to an “outperform” rating on January 20, indicating improved market sentiment. Additionally, Citizens Jmp raised its rating from “market perform” to “market outperform,” setting a price objective of $23.00.
Overall, four analysts currently rate Sutro Biopharma with a “buy” rating, three suggest holding, and two recommend selling. According to MarketBeat, the consensus rating remains “Hold,” with an average target price of $31.83.
Institutional Investors Increase Stakes
Several hedge funds have recently adjusted their positions in Sutro Biopharma, indicating growing interest among institutional investors. Velan Capital Investment Management LP increased its stake by 2.0% during the third quarter, now holding 3,120,000 shares valued at approximately $2.709 million after acquiring an additional 60,000 shares.
UBS Group AG also raised its stake by 14.0%, accumulating 1,845,839 shares worth around $1.602 million. AQR Capital Management LLC made a notable increase, boosting its holdings by 1,052.8% to own 1,320,917 shares valued at $859,000 following a substantial purchase of 1,206,330 shares.
Jane Street Group LLC and Jacobs Levy Equity Management Inc. have also entered new positions in Sutro Biopharma, with respective investments of approximately $492,000 and $387,000. Collectively, hedge funds and institutional investors own around 96.99% of the company’s stock, highlighting strong confidence in its future prospects.
Sutro Biopharma, headquartered in South San Francisco, California, specializes in the discovery and development of innovative biologic drug candidates, primarily focusing on oncology and immunology. The company utilizes its proprietary cell-free protein synthesis platform, XpressCFTM, to create complex proteins that include antibody-drug conjugates and bispecific antibodies. Since its founding in 2003, Sutro Biopharma has built a robust pipeline of immuno-oncology candidates across various stages of development.
For those interested in keeping up-to-date with Sutro Biopharma’s performance, a daily summary of news and analyst ratings is available through MarketBeat’s free subscription service.
